A Phase 3 interventional study of Everolimus and Prograf or Neoral in Kidney Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 77 sites in 21 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to determine whether an early Calcineurin Inhibitor (CNI) to everolimus conversion at 10-14 weeks post transplantation improves renal allograft function without compromising efficacy compared to standard CNI treatment in de novo renal allograft recipients. In addition, the study was designed to evaluate the impact of a CNI-free regimen on evolution of cardiovascular parameters in de novo renal allograft recipients
This was a 24-month, multi-center, randomized, open-label trial with two parallel arms in adult de novo renal allograft recipients. The study consisted of a run-in period from transplantation to Randomization and a treatment period from Randomization until Month 24. At baseline visit, patients were transplanted and entered the run-in period from transplantation (Baseline) to Randomization (week 10-14 post-transplantation). At Week 10-14, eligible patients were randomized into one of the 2 treatment arms: standard CNIs and Myfortic versus everolimus and Myfortic and entered the treatment period of the study from Randomization to Month 24. Patients in both arms received steroids as per center practice and in any caseat least 5 mg/Day. At Randomization, patients were stratified according to their renal allograft function and previous cardiovascular events. The main analysis was performed at Month 12 and the follow-up analysis was performed at Month 24.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria at Baseline:
Inclusion Criteria at Randomization:
Exclusion Criteria at Baseline:
Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
Exclusion Criteria at Randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conversion from CNI to everolimus in combination with Myfortic and steroids
Drug: Everolimus
Control arm: CNI continuation, either Prograf or Neoral in combination with Myfortic and steroids
Drug: Prograf or Neoral
Early CNI to everolimus conversion
Also known as: Certican, Zortress, RAD001
Active CNI-based control (Prograf or Neoral)
Also known as: Tacrolimus or Cyclosporine
Estimated Glomerular Filtration Rate (eGFR)
Assessment of renal function by comparing change from randomization to Month 12 in eGFR (MDRD4) between treatment arms (Full analysis set). Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR \[mL/min/1.73m˄2\] = 186.3\*(C˄-1.154)\*(A˄-0.203)\*G\*R. DEFINITIONS: C = serum concentration of creatinine \[mg/dL\]; A = age \[years\]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1
Time frame: Month 12
Incidence of Composite Efficacy Endpoint for Each Arm at Month 12 and Month 24
Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)\*, (2) graft loss\*\*, or (3) death . \*A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. \*\*Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis or re-transplanted.
Time frame: at 12 months and month 24 post-transplantation
Change in Left Ventricular Mass Index (LVMi) From Randomization to Month 12 and Month 24
Evolution of left ventricular mass and hypertrophy were evaluated by left ventricular mass index (LVMi) assessed by echocardiography. LVMi is derived using a standard formula from dimensional measurements on the echocardiogram. Analysis of covariance was applied with treatment, center (as a random effect), and donor type as factors and LVMi at Randomization as covariate.
Time frame: Randomization, Month 12 and Month 24
Comparison of Incidence Rates of Efficacy Endpoints Between Treatment Arms (Full Analysis Set - 24 Month Analysis)
(treated BPAR ≥ IB, graft loss or death)A comparison of the incidence rates for the individual components of the composite efficacy endpoint between treatment arms
Time frame: at 24 months post-transplantation
Full analysis set (24 month analysis)
| Milestone | Everolimus | Standard CNI (Tac) | Standard CNI (CsA) |
|---|---|---|---|
| Started | 353 | 231 | 125 |
| Completed | 229 | 190 | 93 |
| Not completed | 124 | 41 | 32 |
| Withdrew: Adverse event | 87 | 18 | 17 |
| Withdrew: Abnormal laboratory value(s) | 6 | 0 | 1 |
| Withdrew: Abnormal test procedure result(s) | 3 | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 1 | 2 |
| Withdrew: Subject's no longer required drug | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 18 | 8 | 2 |
| Withdrew: Lost to follow-up | 1 | 4 | 2 |
| Withdrew: Administrative problems | 2 | 1 | 2 |
| Withdrew: Death | 2 | 1 | 2 |
| Withdrew: Graft loss | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 5 | 2 |
| Withdrew: Missing | 2 | 0 | 0 |
| Milestone | Everolimus | Standard CNI (Tac) | Standard CNI (CsA) |
|---|---|---|---|
| Started | 353 | 231 | 125 |
| Completed | 313 | 215 | 111 |
| Not completed | 40 | 16 | 14 |
| Withdrew: Withdrawal by subject | 18 | 6 | 3 |
| Withdrew: Lost to follow-up | 10 | 5 | 7 |
| Withdrew: Death | 8 | 5 | 4 |
| Withdrew: Other | 2 | 0 | 0 |
| Withdrew: Missing | 2 | 0 | 0 |
Assessment of renal function by comparing change from randomization to Month 12 in eGFR (MDRD4) between treatment arms (Full analysis set). Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR \[mL/min/1.73m˄2\] = 186.3\*(C˄-1.154)\*(A˄-0.203)\*G\*R. DEFINITIONS: C = serum concentration of creatinine \[mg/dL\]; A = age \[years\]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1
| mL/min/1.73m^2 | Everolimus | Standard CNI (Tac) | Standard CNI (CsA) |
|---|---|---|---|
| Estimated Glomerular Filtration Rate (eGFR) | 64.1 ± 22.31 | 61.5 ± 19.86 | 58.4 ± 19.62 |
Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)\*, (2) graft loss\*\*, or (3) death . \*A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. \*\*Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis or re-transplanted.
| Number of incidence | Everolimus | Standard CNI (Tac) | Standard CNI (CsA) |
|---|---|---|---|
| Month 12 | 21 | 4 | 8 |
| Month 24 | 27 | 8 | 8 |
Evolution of left ventricular mass and hypertrophy were evaluated by left ventricular mass index (LVMi) assessed by echocardiography. LVMi is derived using a standard formula from dimensional measurements on the echocardiogram. Analysis of covariance was applied with treatment, center (as a random effect), and donor type as factors and LVMi at Randomization as covariate.
| g/m^2.7 | Everolimus | Standard CNI (Tac) | Standard CNI (CsA) |
|---|---|---|---|
| Randomization | 50.30 ± 11.62 | 51.08 ± 14.11 | 51.13 ± 12.70 |
| Month 12 | 49.95 ± 12.63 | 48.98 ± 14.63 | 50.96 ± 13.00 |
| Month 24 | 46.66 ± 12.19 | 45.63 ± 13.50 | 47.91 ± 12.71 |
(treated BPAR ≥ IB, graft loss or death)A comparison of the incidence rates for the individual components of the composite efficacy endpoint between treatment arms
| Number of incidence | Everolimus | Standard CNI (Tac) | Standard CNI (CsA) |
|---|---|---|---|
| Composite failure: tBPAR>=IB, graft loss, death | 27 | 8 | 8 |
| Composite tBPAR>=IB, graft loss, death, loss f/u | 35 | 14 | 15 |
| Composite of graft loss or Death | 10 | 6 | 4 |
| tBPAR>=IB | 18 | 3 | 5 |
| Graft loss | 4 | 2 | 2 |
| Death | 8 | 5 | 4 |
| Suspected Acute rejection | 61 | 27 | 19 |
| Subclinical Acute rejection | 0 | 0 | 0 |
| Acute rejection (AR) | 52 | 14 | 15 |
| Treated Acute rejection (tAR) | 40 | 9 | 14 |
| biopsy proven acute rejection (BPAR) | 37 | 8 | 13 |
| treated biopsy proven acute rejection (tBPAR) | 32 | 7 | 13 |
| tBPAR=IA | 16 | 3 | 8 |
| tBPAR=IB | 14 | 3 | 5 |
| tBPAR=IIA | 3 | 0 | 1 |
| tBPAR=IIB | 2 | 0 | 0 |
| tBPAR=III | 0 | 0 | 0 |
| Antibody tBPAR | 2 | 1 | 1 |
| Antibody mediated rejection (AMR) | 16 | 4 | 3 |
Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus | — | 188/346 (54.3%) | 316/346 (91.3%) |
| Standard CNI (Tac) | — | 118/238 (49.6%) | 216/238 (90.8%) |
| Standard CNI (CsA) | — | 58/121 (47.9%) | 103/121 (85.1%) |
| Event | Everolimus | Standard CNI (Tac) | Standard CNI (CsA) |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 25/346 | 19/238 | 8/121 |
| Transplant rejectionImmune system disorders | 23/346 | 5/238 | 9/121 |
| PyrexiaGeneral disorders | 25/346 | 5/238 | 4/121 |
| Kidney transplant rejectionImmune system disorders | 19/346 | 5/238 | 8/121 |
| Renal failure acuteRenal and urinary disorders | 7/346 | 3/238 | 7/121 |
| Blood creatinine increasedInvestigations | 17/346 | 6/238 | 5/121 |
| DiarrhoeaGastrointestinal disorders | 15/346 | 9/238 | 4/121 |
| GastroenteritisInfections and infestations | 11/346 | 9/238 | 5/121 |
| PneumoniaInfections and infestations | 14/346 | 4/238 | 5/121 |
| PyelonephritisInfections and infestations | 13/346 | 4/238 | 5/121 |
| Event | Everolimus | Standard CNI (Tac) | Standard CNI (CsA) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 79/346 | 55/238 | 13/121 |
| Urinary tract infectionInfections and infestations | 75/346 | 47/238 | 18/121 |
| PyrexiaGeneral disorders | 62/346 | 20/238 | 12/121 |
| Oedema peripheralGeneral disorders | 60/346 | 21/238 | 13/121 |
| Blood creatinine increasedInvestigations | 30/346 | 24/238 | 20/121 |
| ProteinuriaRenal and urinary disorders | 52/346 | 11/238 | 2/121 |
| LeukopeniaBlood and lymphatic system disorders | 48/346 | 35/238 | 11/121 |
| AnaemiaBlood and lymphatic system disorders | 41/346 | 21/238 | 5/121 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 40/346 | 15/238 | 7/121 |
| HypertensionVascular disorders | 35/346 | 24/238 | 12/121 |
Full analysis set (FAS), 24 month analysis
| Age, Continuous(years) | Everolimus | Standard CNI (Tac) | Standard CNI (CsA) | Total |
|---|---|---|---|---|
| Mean | 46.0 ± 14.4 | 47.3 ± 14.5 | 45.4 ± 15.6 | 46.2 ± 14.8 |
| Sex: Female, Male(Participants) | Everolimus | Standard CNI (Tac) | Standard CNI (CsA) | Total |
|---|---|---|---|---|
| Female | 111 | 71 | 33 | 215 |
| Male | 242 | 160 | 92 | 494 |
| Race/Ethnicity, Customized(participants) | Everolimus | Standard CNI (Tac) | Standard CNI (CsA) | Total |
|---|---|---|---|---|
| Caucasian | 246 ± 69.7 | 173 ± 74.9 | 97 ± 77.6 | 516 |
| Black | 4 ± 1.1 | 5 ± 2.2 | 0 ± 0 | 9 |
| Asian | 66 ± 18.7 | 41 ± 17.7 | 20 ± 16.0 | 127 |
| Native American | 1 ± 0.3 | 0 ± 0.0 | 0 ± 0.0 | 1 |
| Pacific Islander | 0 ± 0 | 1 ± 0.4 | 1 ± 0.8 | 2 |
| Other | 36 ± 10.2 | 11 ± 4.8 | 7 ± 5.6 | 54 |
Ran from Aug 2010 to primary completion in Oct 2014, 50 months.
Results were first posted in May 2017, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus